Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with high disease burden and poor outcomes despite androgen deprivation therapy. This activity by Neeraj Agarwal, MD, provides strategies for germline genetic testing and somatic testing to best inform treatment. Poly (ADP-ribose) polymerase (PARP) inhibitor therapy provides a unique approach to treatment. Dr. Agarwal reviews safety and efficacy findings from recent clinical trials for the 2 PARP inhibitors, olaparib and rucaparib, approved in the United States for mCRPC. He also shares observations regarding PARP inhibitors in combination with other therapies.
0.5 AMA PRA Category 1 CreditsTM
This activity was developed for medical oncologists and other healthcare professionals involved in the treatment of prostate cancer.
This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.
Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research
Co-leader, HCI Experimental Therapeutics Program (CCSG Program)
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Salt Lake City, Utah